HT
JUNO

HAP Trading’s Juno Therapeutics, Inc. JUNO Stock Holding History

HAP Trading’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-22,900
Closed -$18K – 1293
2016
Q2 		$18K Buy
+22,900
New +$950K ﹤0.01% 734
2015
Q4 		– Sell
-18,800
Closed -$33K – 1225
2015
Q3 		$33K Buy
+18,800
New +$825K ﹤0.01% 755

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

HAP Trading's JUNO Position: Q1 2017 in Review

HAP Trading sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 10,741 shares — an estimated $202K sold.

HAP Trading first reported a position in JUNO in Q2 2015 and held it in 3 quarters. The position peaked at $880K in Q2 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

  • HAP Trading reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • HAP Trading sold 10,741 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $202K.
  • HAP Trading first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
  • HAP Trading's Juno Therapeutics, Inc. position peaked at $880K in Q2 2015.
  • 157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on HAP Trading's 13F filing for Q1 2017, filed 12 May 2017.